Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Exagen s return on capital employed overview - What They Never Told You

According to Benzinga Pro data, during Q4, Exagen (NASDAQ:XGN) posted sales of $12.69 million. Earnings were up 1.76%, but Exagen still reported an overall loss of $7.05 million. In Q3, Exagen brought in $12.25 million in sales but lost $7.18 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.